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Summary 
Experimental allergic encephalomyelitis (EAE) is an autoimmune disease of the central nervous 
system that can be transferred to naive mice via CD4 + T cells isolated from appropriately im- 
munized mice. We have evaluated the effects of recombinant murine interleukin 12 (rmi1:12), 
a potent inducer of interferon 3/(IFN-3') and promoter ofThl T cell development, on the course 
of adoptively transferred EAE. The transfer of  lymph node cells (LNC) isolated from proteolipid 
protein (PLP)-primed animals and stimulated in vitro with PLP to naive  mice resulted  in a progressive 
paralytic disease culminating in complete hind limb paralysis in the majority of the recipients. 
When mice were injected with LNC that had been stimulated in vitro with PLP in the presence 
of rmi1:12,  the subsequent course of disease was more severe and prolonged. The addition of 
rmlL-12 during the in vitro stimulation with PLP resulted in a 10-fold increase in IFN-'y and 
a 2-fold increase in tumor necrosis factor (TNF) ct in the supernatants,  relative to LNC stimu- 
lated with PLP alone. However, neutralization  of IFN-3, or TNF-c~ in vitro with specific anti- 
bodies did not abrogate the ability of rmlL-12 to exacerbate the subsequent disease. Similarly, 
mice treated with rmi1:12 in vivo after the transfer of antigen-stimulated  LNC developed a more 
severe and prolonged course of disease compared with vehicle-treated control animals. In con- 
trast, treatment of mice with an antibody to murine I1:12 after cell transfer completely prevented 
paralysis, with only 40% of the mice developing mild disease. These results demonstrate that 
in vitro stimulation of antigen primed LNC with PLP and rmlb12 enhances their subsequent 
encephalitogenicity.  Furthermore, inhibition of endogenous IL-12 in vivo after LNC transfer 
prevented paralysis, suggesting  that endogenous  11:12 plays a pivotal role in the pathogenesis 
of this model of autoimmune disease. 
E 
xperimental allergic encephalomyelitis (EAE) is a T cell- 
r  mediated autoimmune disease of the central  nervous 
system (CNS). Disease can be induced in susceptible strains 
of mice by immunization with CNS myelin antigens or, al- 
ternatively, disease can be passively transferred to susceptible 
mice via antigen-stimulated  CD4 + T cells (1). Elimination 
of CD4 + cells, but not CD8 + cells, prevents disease transfer, 
thus confirming the role of CD4 + T cells in disease induc- 
tion. The clinical course of disease is characterized by weight 
loss and hind limb weakness, which commonly progresses 
to bilateral hind limb paralysis. In most species, the disease 
remits spontaneously, with the sequence of recovery being 
the reverse of that of onset. Acute disease is associated with 
the  infiltration  of CD4 +  tymphocytes followed  by  the 
recruitment of monocytes and macrophages into the CNS 
lesions (2). Analysis  of  cytokine profiles in the CNS by mRNA 
expression after the transfer of myelin basic protein (MBP)- 
stimulated lymph node cells (LNC) demonstrated that the 
onset of  disease is associated with cytokine  expression typical 
of a Thl-type immune response, with high levels of I1.2 and 
IFN-'y mRNA (3). In contrast, immunohistochemical  anal- 
>'sis demonstrated that II_.4, a cytokine produced by Th2 cells, 
appeared transiently later in the course of disease as symp- 
toms began to resolve (2). Recovery from disease is also as- 
sociated with a decline in Ib2 and IFN-3~ mRNA and a con- 
comitant rise in Ibl0 mRNA consistent with a Th2-type 
response (3). These changes in cytokine profiles suggest that 
the onset of disease and subsequent spontaneous recovery are 
associated with a switch from a predominantly Thl type re- 
sponse to a more typical Th2-type response within the inflam- 
matory loci. 
The differentiation pathway that leads to the generation 
of CD4 + Thl and Th2 cells is regulated at least in part by 
cytokines released from lymphocytes and accessory  cells, with 
IFN-3{ and I1:4 inducing differentiation to Thl and Th2 cells, 
respectively (4-6).  In addition to Ib4 and IFN-% Ibl0 and 
Ib12 appear to play primary roles in the differentiation  of 
CD4 + T helper cells (7, 8). Ib12 is a novel heterodimeric 
cytokine that enhances NK-mediated cytotoxicity and induces 
IFN-3~ production by NK cells and T lymphocytes (9, 10). 
The ability of  Ib12 to induce IFN-3'- and promote Thl-specific 
immune responses has been demonstrated both in vitro (11) 
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12 following Leishmania major infection rendered susceptible 
BALB/c  mice,  which  normally respond to L.  major with 
preferential expansion of II_,4- and Ibl0--producing Th2 cells, 
resistant to leishmaniasis.  Examination of LNC from these 
Ibl2-cured mice showed induction of Thl T ceils that pro- 
duced high levels of IFN-7 (12). 
Given the association between the onset of EAE and a Thl 
effector T  cell population, we evaluated the role of recom- 
binant murine (rm) IL-12 on the course of adoptively trans- 
ferred EAE using LNC stimulated with a synthetic peptide 
of myelin proteolipid protein (PLP) in SJL/J mice. Here we 
report that IL-12 is a key regulator of immune responsiveness 
in this model of autoimmune disease. 
Materials  and Methods 
Adoptive Transfer of PLP-sensitized LNC.  Female  SJL/J mice 
(7-10  wk)  were purchased from The Jackson Laboratory  (Bar 
Harbor, ME), housed five to a cage, and fed standard rodent chow 
diet with water ad libitum. Mice were immunized in two sites on 
the flank with 75/xg (150 #g total) of mouse PLP peptide com- 
prising residues 139-151 (provided by G. Brown, Genetics Insti- 
tute). PLP was administered in 200 #1 of  CFA containing 2 mg/ml 
Mycobacterium  tuberculosis  H37KA (Difco Laboratories,  Detroit, MI). 
On the day of immunization, mice were injected intravenously  with 
0.75  x  101~  Bordetella  pertussis bacilli (Massachusetts Public Health 
Laboratories, Boston, MA). 10 d after immunization, lymph nodes 
(popliteal,  axiUary, and  brachial) were  harvested and  the cells 
resuspended in RPMI-1640 containing 10% fetal  bovine serum (Hy- 
clone Laboratories, Inc., Logan, UT), 5  x  10 -s M 2-ME,  100 
#g/ml streptomycin, and 100 U/ml penicillin. PLP was added to 
the cultures at 2 #g/ml. After incubation for 96 h, the cells were 
harvested, washed twice, and 30  x  10' cells LNC were injected 
intraperitoneally into naive SJL/J mice. 
ClinicalEvaluation of  Diseas~  After the transfer  ofcuhured LNC, 
recipient mice were monitored for clinical signs of  EAE and scored 
on the following scale: 0.5, distal limp tail; 1.0, complete limp tail, 
1.5, limp tail and hind limb weakness (unsteady gait); 2.0, partial 
hind limb paralysis; and 3.0, complete bilateral hind limb paralysis. 
Mean cumulative scores were calculated by the addition of daily 
EAE scores for individual mice during the course of disease. 
In Vitro  Administration  of  rralbl2 Before Cell Transfer.  Recombi- 
nant murine IIA2 (20 ng/ml) (Genetics  Institute) was added during 
the in vitro stimulation of  LNC with PLP before cell transfer. After 
96 h the cells were washed twice, and 30  x  10' cells were trans- 
ferred to naive SJL/J mice, which were monitored for signs of dis- 
ease. In separate experiments, LNC were cultured with either an- 
tigen alone, antigen plus rmlL12 (20 rig/m1), or antigen plus trolL-12 
plus either a neutralizing antibody to IFN-7 (5 #g/m1) (Endogen, 
Inc., Boston, MA) or 200/~1 of a polydonal rabbit anti-mouse 
TNF-c~ antibody (Genzyme Corp., Cambridge, MA). At the end 
of the culture period, supematants were collected  (pooled  from three 
flasks) and IFN-7  and TNF-~ measured by ELISA (Genzyme 
Corp.).  30  x  106 cells from each culture condition were trans- 
ferred to naive mice, which were monitored for signs of disease. 
In Vivo Administration of traiL12 and Anti-II.,12 Antibody After 
the Transfer  of  PLP.stimulated  LNC.  traiL-12  (0.3 #g/mouse, 200 
/~1 i.p.) was administered to mice after transfer of 30  x  106 PLP- 
stimulated LNC. rmIL-12 was administered on days 0,  1, and 2 
after cell transfer. Control mice received  an equal volume of  vehicle 
alone. To determine if Ib12 is involved in the induction of disease 
after transfer of PLP-stimulated LNC, mice were treated with 200 
#g of a sheep polyclonal antibody against murine IL-12 (provided 
by V. VanCleave, Genetics Institute;  200/zl i.p.) on alternate days 
for either 6 or 12 d total after cell transfer and monitored for clin- 
ical signs of  disease. Control mice received  an equal amount of sheep 
IgG. 
Resuhs 
The Addition of rmlL12 During the In Vitro Stimulation of 
LNC with PLP Exacerbates Clinical Signs of EAE After Cell 
Transfer.  LNC from PLP-immunized mice were stimulated 
in vitro with either PLP alone or PLP and rmIL-12 (20 ng/ml) 
for 96 h, after which time they were tested for their ability 
to transfer disease  to naive SJL/J mice. Control mice that 
received LNC stimulated in vitro with PLP developed din- 
ical signs of disease between days 6 and 8. All seven control 
mice  reached  scores  >~2, with  four  out  of  seven  mice 
progressing to complete hind limb paralysis, which lasted be- 
tween 1 and 4 d (Fig.  1). All the control mice recovered by 
day 19. In contrast, mice that received LNC cultured in vitro 
with PLP and rmIb12 developed severe EAE with rapid onset 
of clinical signs (Fig. 1). By day 6, four out seven mice had 
clinical scores of >12, and all mice developed complete hind 
limb paralysis by day 8.  In this particular experiment, five 
out of seven mice failed to recover from the paralysis. 
To determine the effects of rmIb12 on cytokine produc- 
tion during the in vitro stimulation with antigen, LNC from 
PLP-primed mice were cultured with either PLP alone or 
PLP and rmIb12 (20 ng/ml). After 96 h in culture, IFN-7 
and TNF-c~ in the supernatant were measured by ELISA. The 
addition of rmlL-12 during the in vitro stimulation of LNC 
with PLP resulted in a >10-fold increase in IFN-7 and a 2-fold 
increase  in TNF-oz compared with cells cultured with PLP 
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Figure  1.  Adoptive  transfer of EAE via LNC stimulated in vitro with 
PLP and rmIL-12.  Lymph  nodes were harvested  from mice 10 d after  im- 
munization with PLP and stimulated in vitro with antigen alone (open 
circles)  or antigen  and 20 ng/ml rmlI~12 (solid  circles)  as described  in Materials 
and Methods. The results are presented as mean score -  SEM for sur- 
,riving animals (n = 7 mice). The percentage  of surviving animals in the 
IL-12 group is indicated above  the curve. All control mice recovered  from 
disease. The data are representative  of at least three separate experiments. 
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IFN-3,  TNF-cz  OD  CHP  MCS 
ng/ml  pg/ml 
LNC  +  PLP  5.0  +  0.5  100  _+  1.1  6.1  +  1.2  4/7  16.2  _+  6.4 
LNC  +  PLP  +  rmlL-12  65.3  _+  1.3  195  _+  13.4  4.5  _+  0.5  6/6  35.3  _+  4.5 
LNC  +  PLP  +  rmlL-12  +  anti-IFN-'y  bdl*  183  _+  2.4  5.2  _+  0.5  3/4  30.6  _+  16.5 
LNC  +  PLP  +  rmlL-12  +  anti-TNF-cx  79.8  _+  8.3  bdl  4.0  +  0  4/5  30.3  _+  11.2 
LNC from PLP-immunized mice were stimulated in vitro with PLP alone, PLP and rmlL-12 (20 ng/ml), or PLP and rmlL-12 in the presence  of 
neutralizing antibodies to IFN-"/or TNF-cx  for 96 h  as described in Materials and Methods. At the end of the culture period, supernatants from 
individual flasks were pooled and assayed for the presence of IFN-3' and TNF-cx  by ELISA. 
Data represent mean cytokine determinations from multiple dilutions (• SD). 
After in vitro stimulation with PLP,  30  x  106 LNC were  transferred to naive mice, which were monitored for signs  of disease. 
* Below detection limit. 
CLIP, complete hind limb paralysis  (incidence);  MCS,  mean cumulative score  (• SD);  OD,  day of onset of disease (• SD). 
or TNF-cx was an essential component of the in vitro effects 
of rmlb12 on T cell encephalitogenicity, LNC were stimu- 
lated with PLP and rmlb12 in the presence of neutralizing 
antibodies to IFN-'y or TNF-o~.  The addition of the neu- 
tralizing antibody to IFN-'y during stimulation with PLP 
and rmlb12 completely neutralized assayable IFN-v but had 
no effect on the increase in TNF-ot in the supernatants (Table 
1).  Similarly, neutralization of TNF-c~ during stimulation 
with PLP and rmlb12 had no effect on the increase in IFN-'y 
(Table 1). Furthermore, cells stimulated in vitro with PLP 
and rmlD12 in the presence of neutralizing antibodies to ei- 
ther IFN-'y or TNF-c~  still  induced severe disease in naive 
mice with the same kinetics and duration as that seen after 
the transfer of cells stimulated with PLP and rmlL-12 alone 
(Table  1). 
The Effect of In Vivo Administration of lL-12 on Disease Pro- 
gression.  Mice were treated with rmIL-12 (0.3/~g/mouse, 
i.p.)  or saline  for 3 d  after the transfer of 30  x  106 PLP- 
stimulated LNC and monitored for clinical signs of disease. 
The onset of disease in the saline treated control mice ranged 
between days 6 and 8 after cell transfer, and 80% of the mice 
progressed to full bilateral hind limb paralysis. Peak disease 
in the control mice lasted •3  d, after which time the mice 
spontaneously recovered (Fig.  2). In contrast, although the 
onset of clinical signs in mice treated with rmlI:12 was only 
slightly earlier (day 5),  the subsequent progression to peak 
disease was accelerated, and all mice displayed full hind limb 
paralysis by day 8.  The duration of paralysis  was also sig- 
nificantly extended, lasting up to  14 d  (range,  11-14). 
The Effects of  Anti-II.,12 Antibody  Administration on the Course 
of  Disease.  To determine if endogenous Ib12 is required for 
the successful transfer of disease, mice were treated with 200 
#g of a sheep polyclonal antibody to murine Ib12 every other 
day for either 6 or 12 d after cell transfer. Control mice re- 
ceived an equal amount of sheep IgG. The onset of clinical 
signs in the sheep IgG-treated control mice was similar to 
that seen in untreated mice that received PLP-stimulated LNC 
(day 6-7, Fig. 3 a). All control mice developed signs of dis- 
ease graded I>2 (70% developed full hind limb paralysis). Ad- 
ministration of anti-Ib12 antibody during the first 6 d after 
cell transfer delayed the onset of clinical signs by '~7 d, but 
had no effect on the ultimate severity of disease, with all mice 
reaching a score of >t2 (80% developed full hind limb paral- 
ysis). To determine if this delay of disease after cell transfer 
could be sustained by prolonged administration of anti-Ib12 
antibody, mice were treated every other day for 12 d after 
transfer of PLP primed LNC. This extended treatment with 
anti-IL-12 antibody not only delayed the onset of disease, but 
also dramatically reduced the severity of disease, with no mice 
developing hind limb paralysis and only two out of five mice 
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Figure  2.  The effects of in vivo administration of Ib12 on the adoptive 
transfer of EAE via PLP-stimulated LNC. LNC from PLP-immunized mice 
were cultured in vitro with antigen as described in Materials and Methods 
and transferred to naive mice. rmIb12 (0.3/~g/mouse) was administered 
on days 0, 1, and 2 after cell transfer (solid  circles). Control mice received 
an equal volume of saline (open circles). The data are expressed as mean 
score  •  SEM for surviving animals (n =  5 mice). The percentage of sur- 
viving animals in the II.-12 group is indicated above the curve. All control 
mice recovered from disease. The data are representative of three separate 
experiments. 
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Figure 3.  The effects  of in vivo  administration  of anti-IL-12 antibody 
on the adoptive  transfer  of EAE via PLP-stimulated  LNC. LNC from  PLP- 
immunized  mice  were cultured  in vitro  with antigen  as described  in Materials 
and Methods.  Anti-II~12  antibody  (sheep anti-mouse  polyclonal  antibody, 
200/~g/mouse) was administered  intraperitoneally  starting  on the day of 
cell transfer (solid circles). Control mice received an equivalent amount  of 
sheep IgG (open circles). (a) Mean clinical  score + SEM after administra- 
tion of ~Ib12 antibody  every  other day from day 0 to day 6. (b) Mean 
clinical score + SEM after administration of anti-IL-12 antibody  every 
other day from  day  0 to day 12 (n = 5-7 mice). The data  are representative 
of two (a) and three (b) separate experiments, respectively. 
Discussion 
In this study, we examined the effects of rmlL-12 adminis- 
tration on the development of adoptively transferred EAE 
after stimulation of LNC with a  synthetic peptide corre- 
sponding to mouse myelin PLP residues 139-151. This pep- 
tide has been used previously for the active induction of EAE 
in SJL/J mice (14). Using LNC isolated from PLP-immunized 
mice, the addition of rmlL-12 during the in vitro stimulation 
with antigen exacerbated the subsequent clinical signs of dis- 
ease after cell transfer. A similar effect on disease severity was 
seen when spleen  cells were used to transfer disease (data 
not shown). These results suggest that in vitro stimulation 
with rmlL-12 had direct effects on T  cell effector function 
and/or number, ultimately rendering these cells more encepha- 
litogenic. 
Previous  studies  have  demonstrated  that  MBP-specific 
CD4 §  T  cells  secreting cytokines associated  with a  Thl 
phenotype effectively transferred EAE (15). Consistent with 
this finding, we observed increases in both IFN-3~ and TNF-c~ 
in the supernatant of LNC cultures after stimulation in vitro 
with PLP and rmlb12 compared with cells cultured with 
antigen alone. Since the production of these secondary cyto- 
kines after stimulation with rmlb12 could have effects on 
accessory cells, we added neutralizing antibodies against IFN-y 
or TNF-ot to our in vitro cultures. The observation that neu- 
tralization of these cytokines did not affect the ability of 
rmlb12 to exacerbate disease after cell transfer supports the 
conclusion that rmlL-12 has a direct effect on T cell effector 
function and/or number and argues against secondary effects 
mediated by IFN-3/or TNF-o~ during the in vitro stimula- 
tion with PLP, In addition, these antibody blocking experi- 
ments indicate that, in this setting, the stimulation of either 
IFN-3' or TNF-c~ by rmlb12 is independent of the produc- 
tion of the other. Although the data strongly suggest a di- 
rect effect of rmlL-12 during the in vitro stimulation with 
PLP, this cannot be unequivocally stated, as it is possible that 
some bioactive cytokine is present in the cultures despite the 
absence of detectable levels of IFN-3' and TNF-ot by ELISA. 
Although there was a marked increase in both IFN-3, and 
TNF-ot production in cultures treated with rmlL-12, it is not 
clear if this reflects the preferential expansion of Thl effector 
cells, or, alternatively, results from an increase in the produc- 
tion of these cytokines on a per cell basis. To address the effects 
of rmlb12 on the in vitro responsiveness  to PLP, prolifera- 
tion was measured by [3H]thymidine incorporation of LNC 
after PLP stimulation. We were unable to demonstrate a differ- 
ence in antigen-stimulated proliferation in the presence  of 
rmlL-12 when PLP was added at the concentration used to 
transfer disease (2/~g/ml). There was, however, an enhanced 
proliferative  response  at  low concentrations of PLP (0.01 
/zg/ml) in the presence  of rmlL-12  (data  not shown), sug- 
gesting that rmlL-12 could enhance the expansion of PLP- 
responsive T cells in vitro. The observation that rmlL-12 did 
not enhance proliferation at higher doses of antigen may be 
due to increased production of other cytokines in these cul- 
tures, particularly IL-2, which could mask the effects ofrmlbl2 
on a subset of T  cells. 
A profound effect on the course of EAE was also seen when 
rmlL-12 was administered in vivo after the transfer of PLP- 
stimulated LNC. This in vivo treatment with rmlL-12 ac- 
celerated the progression to complete hind limb paralysis and 
resulted in a severe and prolonged clinical course of disease. 
Histological and immunohistochemical evaluation of the 
inflammatory loci of mice killed at peak disease confirmed 
the presence  of multiple perivascular  lesions  typical of the 
clinical pathology associated  with EAE (data not shown). 
Although there were no dramatic differences between rmlb 
12-treated and control mice in either the cellular composi- 
tion of the lesions or in the relative extent of IFN-3/staining, 
preliminary results suggest an increase in the number of inflam- 
matory lesions in rmll.-12-treated mice, which could account 
for the enhanced disease severity (Waldburger, K., unpub- 
lished observation). An extensive histological analysis to de- 
termine the nature of the inflammatory response during the 
course of  EAE after rrnlL-12 administration is being conducted. 
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independent of secondary IFN-3' stimulation, as the combi- 
nation of rmlb12 and a neutralizing anti-IFN-3, antibody 
in vivo after cell transfer resulted in a rapid progression of 
disease, which proved lethal in all mice (Leonard, J. P., K. E. 
Waldburger, and S. J. Goldman, unpublished observations). 
Taken together with the observation by us and others that 
treatment with a neutralizing anti-IFN-3, antibody alone ex- 
acerbates disease (16), these data suggest that rmlIA2 directly 
activates encephalitogenic T cells in vivo, although we cannot 
exclude the contribution of secondary effects mediated by 
TNF-cr 
The most compelling evidence for an immunoregulatory 
role of II.-12 in the pathogenesis of EAE came from experi- 
ments in which endogenous IL-12 was blocked after the transfer 
of PLP-stimulated LNC. In these studies, treatment of mice 
with anti-IL-12 antibody during the first 6 d after cell transfer 
significantly delayed the onset of clinical signs; however, the 
ultimate severity and duration of disease was not affected. 
In contrast, extending the period of antibody treatment to 
12 d completely prevented the development of hind limb pa- 
ralysis. These data suggest that endogenous 1I.-12 is essential 
for the effective transfer of disease  and demonstrate that 
prolonged inhibition of endogenous I1.-12 can prevent paral- 
),sis and substantially reduce the incidence and severity of clin- 
ical signs. Preliminary experiments have demonstrated some 
beneficial effects of anti-Ib12 antibody when given therapeu- 
tically; anti-Ib12 antibody treatment commencing at the time 
of onset of disease (1 wk after transfer) and continuing for 
a period of 6 d resulted in a reduction in the rate of disease 
progression, although the ultimate severity was not changed 
(Leonard, J.  P.,  unpublished observation). 
Inhibition of endogenous Ib12 by an anti-IL-12 antibody 
produced changes in the kinetics of disease transfer very similar 
to those seen after inhibition of integrin-mediated cell adhe- 
sion (15). Interactions between lymphocytes and endothelial 
cells appear to play a major role in regulating the entry of 
antigen specific cells into the CNS (17, 18). By use of PLP- 
specific T  cell clones, the expression of the oe431 integrin 
(very late antigen 4 [VLA-4]) was found to be a prerequisite 
for the successful transfer of EAE (19). In addition, antibodies 
directed against VLA-4 blocked both lymphocyte and mono- 
cyte binding to vessels on EAE brain slices (20) and delayed 
the onset of disease after transfer of MBP-specific T cell clones 
(15). Similarly, antibodies against vascular cell adhesion mol- 
ecule 1, the endothelial cell ligand for VLA-4, delayed the 
onset of disease after the transfer of MBP-specific T cell clones 
or MBP-stimulated LNC (15). Interestingly, the continued 
administration of anti-VLA-4 antibody delayed the onset of 
clinical  signs and reduced the severity of disease  (15) in a 
manner similar to that seen by use of an antibody against 
murine I1.-12. In our studies, the slightly earlier onset of dis- 
ease and rapid progression to complete hind limb paralysis 
after rmlb12 administration in vivo, as well as the delayed 
onset of disease after administration of an antibody to II.-12 
in vivo, are consistent with modulation of integrin adhesion 
function as a potential component contributing to the effects 
of I1.-12 in this model. 
The requirements for successful transfer of EAE via either 
antigen-stimulated primary LNC or antigen-specific CD4 + 
T  cell lines or clones are complex and incompletely under- 
stood. The results of our experiments with an adoptive transfer 
model of EAE support a major role for Ib12 in regulating 
the T  cell response to PLP and, consequently, the severity 
of transferred disease. More importantly, the data show that 
IL-12 is required in vivo for efficient effector function in this 
model. The ability of Ib12 to stimulate Thl T cells and its 
pivotal role in regulating effector function may have significant 
implications for the etiology of autoimmune diseases such 
as multiple sclerosis. 
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